Testing a new antibody to treat chronic hepatitis B infection
Official title: First-in-human study of a potent anti-HBsAg neutralizing antibody
Funded at Rockefeller University · NIH-11035143 · Data updated 2026-11-12
This study is testing a new treatment that uses a special antibody to help lower the levels of hepatitis B in people with chronic hepatitis B, with the hope of boosting their immune system and moving closer to a cure.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 20, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $822,075 |
| NIH project number | 5U01AI167786-03 |
| Project ID | NIH-11035143 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic hepatitis B infection who have not responded adequately to existing antiviral therapies.
✕Less likely to help
Patients with acute hepatitis B infection or those who have already achieved a functional cure may not benefit from this research.
What this research studies
This research investigates a novel human monoclonal antibody designed to neutralize the hepatitis B surface antigen (HBsAg), which is crucial in managing chronic hepatitis B infection. The study aims to assess the antibody's ability to reduce HBsAg levels in patients, potentially restoring their immune response against the virus. By decreasing HBsAg, the research hopes to alleviate immune exhaustion and promote a functional cure for chronic hepatitis B. Participants will receive the antibody treatment and be monitored for its effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that helps clear hepatitis B virus from the body and improves patients' immune responses.
How similar studies have gone: Previous research has shown promise with antibody therapies in treating viral infections, suggesting potential success for this novel approach in hepatitis B.
Where this research is happening
-
Rockefeller University
New York, United States Active
Researchers
- Principal investigator: Caskey, Marina — Rockefeller University
- Study coordinator: Caskey, Marina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.